Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-22-TSCRP-IDA: DOD, Tuberous Sclerosis Complex Research Program, Idea Development Award

Closed Closed July 28, 2022 Opportunity W81XWH-22-TSCRP-IDA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.

• Total funding$2.4 million
• Expected awards3
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the Idea Development Award: Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative. Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative: -Explores a novel idea and/or research question in TSC research and/or patient care. -Uses or develops novel methods or technologies to address a question in TSC research and/or patient care. -Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are expected. New-to-the-Field Investigator: The FY22 TSCRP Idea Development Award mechanism encourages applications from investigators in the early stages of their TSC research career. The New-to-the-Field Investigator Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. Applications to the New-to-the-Field Investigator Option will compete separately from Established Investigators submitting to the regular Idea Development Award.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.